Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Contract manufacturer Lonza will build a plant in Visp, Switzerland, to supply rucaparib, the active ingredient in Clovis Oncology’s PARP inhibitor. Lonza will open a new production line in 2019 that will provide dedicated supply until 2025. Rucaparib targets cancer by inhibiting the DNA-repair enzymes poly-ADP ribose polymerase-1, 2, and 3. It is under FDA priority review for treating advanced ovarian cancer with a decision to come by February 2017.
This article has been sent to the following recipient: